Progentos emerges with $65M for multiple sclerosis trials with IP from Frequency

A new biotech emerged to take for­ward the lead pre­clin­i­cal work de­vel­oped by Fre­quen­cy Ther­a­peu­tics, a re­gen­er­a­tive med­i­cines com­pa­ny that gave up its Nas­daq spot in a re­verse merg­er with Ko­r­ro Bio last year.

Known as Prog­en­tos Ther­a­peu­tics, the Wa­ter­town, MA-based start­up has raised $65 mil­lion in Se­ries A fund­ing, the com­pa­ny told End­points News. For­bion, based in the Nether­lands, led the fi­nanc­ing. Al­ta Part­ners, Mis­sion Bio­Cap­i­tal, Long­wood Fund and Dol­by Fam­i­ly Ven­tures al­so backed the new com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.